P2Y12 receptor as a new target for electroacupuncture relieving comorbidity of visceral pain and depression of inflammatory bowel disease

Yanzhen Li¹, Hong Zhang¹, Jingwen Yang²*, Muoyuang Zhan¹, Xuefei Hu¹, Yongmin Liu¹, Lingling Yu³, Xiaochen Yan⁵, Shangdong Liang⁴, Ruyue Zhang¹, Ying Lu¹, Beining Li¹, Cunzhi Liu² and Man Li¹*

Abstract

Background: The P2Y12 receptor is a kind of purinoceptor that is engaged in platelet aggregation, and P2Y12 inhibitors have been used in clinical antithrombotic therapy. The P2Y12 receptor in microglia induces interleukin-1β (IL-1β) expression, which is a key mediator of depression in the brain. Although peripheral P2Y12 is involved in neuropathic pain, whether P2Y12 expression in the medial prefrontal cortex (mPFC) is associated with comorbidities of visceral pain and depression remains unclear. Accumulating evidence suggests that electroacupuncture (EA) is effective in treating inflammatory bowel disease (IBD), but its mechanism is unknown. This study aimed to determine whether P2Y12 expression in the mPFC is associated with comorbidities of visceral pain and depression in IBD and whether EA treats IBD by targeting the P2Y12 receptor.

Methods: We used 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced IBD mice. P2Y12 short hairpin RNA (shRNA) was stereotaxically injected into the bilateral mPFC. EA was performed on bilateral "Dachangshu" (BL25) acupoints once a day for 7 days. Von Frey filaments and colorectal distension were used to detect the mechanical pain threshold and visceral pain sensitivity. The sucrose preference test, tail suspension test and forced swimming test were used to evaluate depression in mice. Western blotting was used to test the expression of P2Y12 and IL-1β. Immunofluorescence staining was used to assess microglial activity.

Results: We found that IBD mice presented visceral pain and depression associated with increased P2Y12 expression in the mPFC. P2Y12 shRNA significantly attenuated visceral pain and depression in IBD mice. P2Y12 shRNA significantly downregulated IL-1β expression and inhibited the activation of microglia in the mPFC of IBD mice. Meanwhile, EA played a similar role of P2Y12 shRNA. EA significantly downregulated P2Y12 expression, weakened the activation of microglia, and then inhibited IL-1β expression in the mPFC, thus relieving visceral pain and depression in IBD mice.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusion: The present study provided new ideas that the P2Y12 receptor in the mPFC could be a new target for the treatment of comorbid visceral pain and depression by EA. This may not only deepen our understanding of the analgesic and antidepressant mechanisms of EA but also promote the application of EA to treat IBD.

Keywords: P2Y12 receptor, Visceral pain, Depression, EA, IBD

Background
Comorbidity of visceral pain and depression occurs with extremely high prevalence at any age [1]. A growing body of evidence has shown that patients with inflammatory bowel disease (IBD) have a higher incidence of comorbidities of depression and anxiety than healthy persons [2, 3]. Similarly, depression is associated with an increased risk of incident IBD [4, 5]. Although new therapeutic strategies in IBD have transformed from symptom control to treat-to-target algorithms, emotional symptoms are often ignored [6].

The P2Y12 receptor is a kind of metabotropic purinoceptor. It is mainly expressed in platelets, and P2Y12 inhibitors have been widely used in clinical antithrombotic therapy [7, 8]. Recently, the P2Y12 receptor was also found to be expressed in microglia, such as satellite glial cells and microglial cells [9, 10]. Inhibition of microglial P2Y12 suppressed interleukin-1β (IL-1β) release, and P2Y12-deficient microglia displayed reduced IL-1β mRNA expression and release in vitro [11]. In addition, IL-1β in the brain is a key mediator of depression-like behavior induced by acute and chronic stress [12]. Although peripheral P2Y12 is involved in the pathologic changes of neuropathic pain, whether the expression of P2Y12 in the brain is associated with comorbidity of visceral pain and depression in IBD mice remains unclear [13]. In addition, the medial prefrontal cortex (mPFC) handles the emotional and cognitive components of pain, which contributes to the development of chronic pain [14]. There is also evidence that dysfunction of the mPFC in brain activity is closely related to neuropsychiatric diseases, such as depression [15]. It is worth exploring whether the P2Y12/IL-1β pathway in microglia of the mPFC contributes to the comorbidity of visceral pain and depression in IBD.

Electroacupuncture (EA) can carry electric current to acupuncture points through needles connected to an electrical stimulator, which is transmitted to the spinal cord through sensory nerves, then to the brainstem, hypothalamus and higher center [16]. Growing evidence has shown that EA can relieve pain and induce lasting analgesia [17–19]. Studies have also revealed that EA has an antidepressant effect [20–24]. Recently, a clinical study showed that acupuncture can be used as a new therapy for the improvement of gastrointestinal symptoms and noncolonic situations, such as depression of irritable bowel syndrome [25]. However, whether EA improves the comorbidity of visceral pain and depression in IBD mice by regulating P2Y12 expression in the mPFC remains unknown, which severely hinders the clinical practice of EA in treating IBD.

Therefore, in the present study, we first investigated the change in P2Y12 in the mPFC of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced IBD mice. To understand the role of the P2Y12 receptor in the comorbidity of visceral pain and depression, we used P2Y12 short hairpin (shRNA) to interfere with the expression of P2Y12 in the mPFC of IBD mice and then assessed visceral pain and depression-like behavior changes, as well as the protein expression of IL-1β and the activity state of microglia in the mPFC of IBD mice. Finally, we determined whether EA at bilateral Dachangshu (BL25) regulates the expression of P2Y12 in the mPFC and then inhibits the activation of microglia and the expression of IL-1β in the mPFC, thereby alleviating visceral pain and depression in IBD mice. We aimed to explore whether the upregulation of P2Y12 in the mPFC is associated with comorbidities of visceral pain and depression in IBD mice and clarify the mechanism by which EA improves the comorbidity of visceral pain and depression in IBD mice by downregulating P2Y12 expression in the mPFC.

Materials and methods
Animals
A total of 80 eight-week-old male C57BL/6 mice (weighing 20–25 g) were used in this study. All animals were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. Half of the mice were randomly divided into four groups (control, TNBS, EA, and sham EA). The other mice were randomly divided into four groups (control + vectors, TNBS + vectors, control + P2Y12 shRNA, TNBS + P2Y12 shRNA). All animals were housed in cages with a 12 h light/dark cycle and were given free access to food and water. Mice were housed under a controlled environment at a constant temperature of 22–25 °C and humidity of 50±10%.

P2Y12 shRNA treatment
We amplified the shRNA coding sequence of P2Y12 by reverse transcription polymerase chain reaction and ligated it into the GV493 plasmid to generate LV-P2ry12-RNAi (Shanghai Genechem Co., Shanghai, China), and
LV-GFP was used as a control. The titer of the lentivirus was $1 \times 10^9$ titer units (Tu)/ml. ShRNA injections were performed three weeks before modeling. Mice were anesthetized with 10 ml/kg intraperitoneal injection of pentobarbital and fixed on a stereotaxic apparatus (RWD Instruments, China). After disinfection, the bregma and lambda points were exposed, and the balance was corrected. The coordinates were set according to the mouse brain atlas, and holes were drilled on the skull with a dental drill. Desired viral vectors were injected into the bilateral mPFC (AP: +2.0 mm, ML:±0.4 mm, DV: -2.4 mm) using a microsyringe (1 μl, Hamilton, NV, USA) with a glass electrode attached to the front end. Injection occurred at a speed of 30 nl/min. P2Y12 shRNA sequence: GGTCTAGTTTGGCAGGAAA and empty virus sequence: TTCTCCGAACGTGTACGTT.

**TNBS-induced IBD mice**

The day before modeling, the mice were kept in a fasting and water-only environment. The mice were anesthetized with 80 mg/kg pentobarbital (20% ethanol) administered intraperitoneally. TNBS was obtained from Sigma–Aldrich, St. Louis, MO, USA. A PVC-Fr4 catheter (Φ2.7 mm, YN Medical Instrument, Yangzhou, China) was inserted at a depth of approximately 4 cm into the anus of the colon, and the other end was connected to a 1 ml syringe. Mice in the TNBS group were injected with 50 μl of TNBS (5% w/v) and 50 μl of absolute ethanol through a catheter to induce IBD [26]. Mice in the control group were injected with 50 μl of absolute ethanol and 50 μl of distilled water. After the lysate was infused, the mice were placed head down for 1 min.

**EA treatment**

One day after the IBD were established, the mice in the EA group were treated with EA. A Han's Acupoint Nerve Stimulator (Hans-200A, Jisheng Medical Technology Co., Ltd., Nanjing, China) was used to stimulate the bilateral "Dachangshu" (BL25) of mice once a day for 7 days. EA was carried out at 1 mA and 2 Hz for 30 min. For the sham EA group, needles were inserted at the same acupoints, but Han’s acupoint nerve stimulator was not connected, and no other operations were performed. During EA treatment, the mice were placed into a homemade 10 cm square denim pocket. In the control group and the TNBS group, the mice were put into the pocket without any treatment. During treatment, the mice remained awake and showed no obvious signs of distress.

**Mechanical sensitivity test**

Mechanical pain was tested with von Frey filaments. Before the test, the mice were placed in the testing environment to adapt for 30 min. Before modeling with TNBS, the mice were tested for mechanical threshold for three days, and the average value was used as the baseline threshold. After the injection of TNBS, the mice were subjected to a nociceptive threshold test after EA treatment for 7 consecutive days. The mechanical threshold was measured by the “up and down” method. The mouse was placed in an organic plastic box with a metal mesh pad at the bottom, and von Frey filaments were used to apply a vertical force to the mouse’s left hind paw for 6 s. Lifting the foot or licking was considered a positive response, and the statistics were calculated as the average of two tests performed at a 5-min interval.

**Visceral hyperalgesia test**

After other behavioral experiments, colorectal dilatation (CRD) was used to evaluate the degree of visceral hyperalgesia, and the abdominal withdrawal reflex (AWR) of the mice was recorded. The scoring standard refers to Al-Chaer’s method [27]: no behavioral response to CRD, scored as 0 points; given to stimulated mice with short head or body movements, scored as 1 point; abdominal muscle contraction during stimulation, scored as 2 points; lifted abdomen, scored as 3 points; body arched and the pelvis and scrotum are lifted, scored as 4 points. Before the test, the mice were placed in a plexiglass compartment (20 cm × 20 cm × 10 cm) for 5 min. A children's scalp needle infusion set was used as a catheter. One end of the catheter was connected to the balloon, and the other end was connected to a 10 ml syringe and a blood pressure meter through a three-way joint. The balloon was inserted into the rectum until the catheter was positioned into the anus (2 cm away from the end of the balloon). The catheter was fixed at the bottom of the tail to prevent it from falling off, and the CRD test was performed with stepwise pressure (20/40/60/80 mmHg). Each pressure value was measured twice, lasting 30 s, with an interval of 4 min, and the average value was taken.

**Sucrose preference test**

Mice were single housed in cages with a water shortage for 6 h and were given two identical water bottles for 24 h, one containing sucrose water (1.5%) and the other containing ordinary water. Twelve hours later, the positions of the two bottles were changed. The weight of the water bottle was recorded before and after the test. A mouse's preference for sucrose was recorded as sucrose consumption (g) / (sucrose consumption (g) + water consumption (g)).

**Forced swimming test**

Mice were placed in a plastic cylinder filled with water to 20 cm from the bottom under usual illumination. The
behavior of mice was recorded by a camera. The duration of immobility was counted by the same person during the study as the time when the animals remained floating without any movement of either the head or the four limbs. Only the last 4 min of trials were analyzed.

**Tail suspension test**
A tape was attached from the tip to a 1–2 cm position on the tail of the mouse, and the mouse was hung at a height of 30 cm on a horizontal rod. A cylindrical plastic tube was placed at the bottom of the tail to prevent the tail from climbing. The mice were suspended for 6 min, and video recordings of quantitative tests were obtained. The total time spent in the stationary posture was measured.

**Enzyme-linked immunosorbent assay**
IL-1β levels were measured by a Mouse Interleukin 1β (IL-1β) ELISA Kit (Chuangxiang Biological Technology Co., Shanghai, China) as described in the manufacturer’s instructions. The tissues were collected using 0.09% NaCl and then centrifuged for 30 min at 3000 g at 4 °C within 30 min of collection. Ten microliters of testing sample and 40 µl of sample diluent were added to the testing sample well. Then, 100 µl of HRP-conjugated reagent was added to each well, covered with an adhesive strip and incubated for 60 min at 37 °C. Chromogen solution A (50 µl) and chromogen solution B (50 µl) were added to each well and incubated for 15 min at 37 °C in the dark, and then stop solution was added to each well. A microtiter plate reader was used to read the optical density (O.D.) at 450 nm. The IL-1β concentration in the brain tissues was calculated from standard curves.

**Western blot**
The protein of the collected mouse brain tissues was extracted using cold lysis buffer containing protease inhibitor. The protein concentrations were determined by the bicinchoninic acid (BCA) method (Beyotime Biotechnology, Shanghai, China). Equal amounts of protein from different samples were separated using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gels and then electrotransferred onto a 0.45-µm polyvinylidene fluoride (PVDF) membrane (Millipore, USA). After the membrane was immersed in 3% bovine serum albumin (BSA) for 2 h, target proteins were detected using primary antibodies, including rabbit anti-P2Y12R antibody (1:800), rabbit anti-IL-1β antibody (1:800), and rabbit anti-β-actin antibody (1:1000). Horseradish peroxidase (HRP)-conjugated secondary antibodies were incubated at 37 °C for 40 min. Immunoreactive bands on the membrane were visualized by enhanced chemiluminescent detection (Beyotime Biotechnology, Shanghai, China). The relative expression abundance was tested by ImageJ software (NIH, Bethesda, MD, USA).

**Immunofluorescence**
Animals were anesthetized after the behavioral experiment. The brains were dehydrated for 24 h in 10% sucrose, 20% sucrose and 30% sucrose in succession after postfixation in 4% paraformaldehyde overnight. These samples were cut into 20 µm thick coronal sections and then used for rabbit anti-IBA-1(1:200) or mouse anti-CD68 (1:400) immunohistochemistry staining. Then, the tissues were incubated with secondary antibodies from Jackson ImmunoResearch: donkey anti-rabbit IgG conjugated with DyLight 594 (1:600), and donkey anti-mouse IgG conjugated with DyLight 594 (1:400). The reaction product was visualized and captured by a digital fluorescence microscope (Olympus), the percentage of IBA-1-positive cells was quantified by Strata Quest 7.0 and the percentage of CD68-positive area was quantified by ImageJ software.

**Statistical analysis**
All data are presented as the mean±SEM. GraphPad Prism 8 software (Inc., La Jolla, CA, USA) was used in this study for data analysis. A t test was used to analyze significant differences between two groups. Ordinary one-way analysis was used, followed by Tukey’s multiple comparisons test. For visceral pain and mechanical sensitivity, two-way multiple comparisons with Bonferroni’s multiple comparisons test were used. A value of P<0.05 was considered statistically significant.
Results
TNBS-induced IBD mice presented comorbidities of visceral pain and depression and upregulation of P2Y12 expression in the mPFC of IBD mice
Von Frey filaments were used to evaluate mechanical allodynia. The mechanical pain threshold of mice was remarkably reduced in the TNBS group compared with that of the control group (Fig. 1a, P < 0.05). The AWR score of CRD was used to assess visceral hypersensitivity in IBD mice. The AWR score in the TNBS group was higher than that of the control group (Fig. 1b, P < 0.05). SPT was used to evaluate depression-like behavior in IBD mice. The intake of sucrose water in the TNBS group was lower than that of the control group (Fig. 1c, P < 0.05). P2Y12 expression was upregulated in the TNBS group compared with the control group (Fig. 1d, e, P < 0.05). Fluorescence immunohistochemistry showed similar results (Fig. 1f). In summary, mechanical allodynia, visceral hypersensitivity and depression-like behaviors occurred, and the expression of P2Y12 was upregulated in the mPFC of IBD mice.

P2Y12 shRNA treatment relieved the comorbidity of visceral pain and depression in IBD mice
To demonstrate whether P2Y12 shRNA treatment alleviated mechanical allodynia and visceral pain in IBD mice, von Frey filaments and the AWR score of CRD were used. A schematic diagram of P2Y12 shRNA injection (Additional file 1: Fig. S1a, b) and RT–PCR was used to analyze transfection efficiency (Additional file 1: Fig. S1, c). Compared with the control + vectors group, the mechanical pain threshold was decreased in the TNBS + vectors group. Compared with the TNBS + vectors group, the mechanical pain threshold was remarkably increased in the TNBS + P2Y12 shRNA group (Fig. 2b, P < 0.05), which revealed that P2Y12 shRNA treatment relieved mechanical allodynia in IBD mice. Compared with the control + vectors group, the AWR score of CRD was increased in the TNBS + vectors group. The AWR score
Fig. 2  P2Y12 shRNA relieved the mechanical allodynia, visceral hyperalgesia and depression-like behaviors in IBD mice. 

**a** Experimental flowchart. 
**b** Time course of mechanical threshold with P2Y12 shRNA treatment. 
**c** Visceral hyperalgesia was evaluated by CRD. 
**d** After P2Y12 shRNA treatment, mice's preference for sucrose was recorded as: sucrose consumption (g) / (sucrose consumption (g) + water consumption (g)) × 100%. 
**e** Representative results of the effect of the P2Y12 shRNA treatment on the proportion of floating time in the FST. The proportion of floating time was recorded as: (Floating time (s)/total time (s)) × 100%. 
**f** Representative results of the effect of the P2Y12 shRNA treatment on the proportion of immobility time in the TST. The proportion of immobility time was recorded as: (Immobility time (s)/total time (s)) × 100%. 

The data are expressed as mean ± SEM (n = 6–9 mice). *p < 0.05, compared with the control + vectors group; #p < 0.05, compared with the TNBS + vectors group.
of CRD in the TNBS + P2Y12 shRNA group was lower than that in the TNBS + vectors group (Fig. 2c, P < 0.05). The results indicated that P2Y12 shRNA treatment reversed visceral hypersensitivity in IBD mice.

To investigate whether P2Y12 shRNA treatment attenuated depression in IBD mice, SPT, TST and FST were used. Compared with the control + vectors group, the sucrose water intake was decreased in the TNBS + vectors group. The sucrose water intake in the TNBS + P2Y12 shRNA group was higher than that in the TNBS + vectors group (Fig. 2d, P < 0.05). However, there was no significant difference in the proportion of floating time of each group in the FST (Fig. 2e, P > 0.05). Compared with the control + vectors group, the proportion of immobility time was increased in the TNBS + vectors group. The proportion of immobility time in the TNBS + P2Y12 shRNA group was less than that in the TNBS + vectors group (Fig. 2f, P < 0.05). The data demonstrated that P2Y12 shRNA relieved depression-like behaviors in IBD mice.

**P2Y12 shRNA treatment downregulated the expression of P2Y12 and IL-1β and weakened the activation of microglia in the mPFC of IBD mice**

To test whether injecting P2Y12 shRNA into the mPFC alters the expression of P2Y12 and IL-1β, western blotting and ELISA were used. Compared with that in the control + vectors group, the expression of P2Y12 was increased in TNBS + vectors group. Compared with TNBS + vectors group, the expression of P2Y12 was decreased in the TNBS + P2Y12 shRNA group (Fig. 3a, d, P < 0.05). The expression of IL-1β in the TNBS + vectors group was higher than that in the control + vectors group. Compared with that in the TNBS + vectors group, the expression of IL-1β was decreased in the TNBS + P2Y12 shRNA group (Fig. 3b, e, P < 0.05). ELISA showed similar trends of IL-1β by western blotting (Fig. 3c, P < 0.05). In summary, the expression of IL-1β was downregulated by P2Y12 shRNA treatment in the mPFC of IBD mice.

Microglia were stained red with IBA-1, and nuclei were stained blue with DAPI (Fig. 4a, b). Compared with the control + vectors group, the percentage of IBA-1-positive cells in the TNBS + vectors group was increased. Compared with that in the TNBS + vectors group, the percentage of IBA-1-positive cells in the TNBS + P2Y12 shRNA group was significantly decreased (Fig. 4c, P < 0.05). Then, activated microglia were stained red with CD68 (Fig. 5a, b), and nuclei were stained blue with DAPI (Fig. 5c, d). Compared with the control + vectors group, the percentage of CD68-positive area in the TNBS + vectors group was increased. Compared with that in the TNBS + vectors group, the percentage of CD68-positive area in the TNBS + P2Y12 shRNA group was significantly decreased (Fig. 5e, P < 0.05). The data demonstrated that microglial activation was inhibited by P2Y12 shRNA treatment in the mPFC of IBD mice.

**Fig. 3** P2Y12 shRNA treatment downregulated the expression of P2Y12 and IL-1β in the mPFC. 

- **a** Representative immunoblots of P2Y12 and β-actin protein expression in the mPFC. 
- **b** Representative immunoblots of IL-1β and β-actin protein expression in the mPFC. 
- **c** Enzyme-linked immunosorbent assay results. 
- **d** Densitometric analysis of P2Y12 protein normalized to the loading control. 
- **e** Densitometric analysis of IL-1β protein normalized to the loading control. 

Data are presented as the mean ± SEM (n = 3–4). *p < 0.05, compared with the control + vectors group; #p < 0.05, compared with the TNBS + vectors group.
EA relieved the comorbidity of visceral pain and depression in IBD mice

Compared with the control group, the mechanical pain threshold was remarkably reduced in the TNBS group (Fig. 6b, P < 0.05), which indicated that TNBS caused mechanical allodynia in mice. On the 3rd day, compared with the TNBS group, the mechanical pain threshold was significantly increased in the EA but not the sham EA group (Fig. 6b, P < 0.05). On the 4th day, compared with the sham EA group, the mechanical pain threshold was significantly increased in the EA group (Fig. 6b, P < 0.05). The data indicated that EA relieved mechanical allodynia in IBD mice and that sham EA was not effective. The AWR score of CRD in the TNBS group was higher than that in the control group (Fig. 6c, P < 0.05). Compared with the TNBS group, the AWR score of CRD in the EA but not the sham EA group significantly decreased (Fig. 6c, P < 0.05). Compared with the sham EA group, the AWR score of the CRD was significantly decreased in the EA group (Fig. 6c, P < 0.05). The results indicated that EA reversed visceral hypersensitivity in IBD mice.

In the SPT, compared with the control group, the sucrose water intake in the TNBS group was decreased (Fig. 6d, P < 0.05). Compared with the TNBS group, the sucrose water intake in the EA but not the sham EA group was increased (Fig. 6d, P < 0.05). Compared with the sham EA group, the sucrose water intake in the EA group was increased (Fig. 6d, P < 0.05). In the TST and FST, compared with the control group, the proportion of floating time and the proportion of immobility time in the TNBS group were increased (Fig. 6e, f, P < 0.05). Compared with the TNBS group, the proportion of floating time and the proportion of immobility time in the EA but not the sham EA group were decreased (Fig. 6e, f, P < 0.05). There was no difference between the EA group and the sham EA group in the FST (Fig. 6e, P < 0.05). In the TST, compared with the sham EA group, the proportion of immobility time in the EA group was decreased (Fig. 6f, P < 0.05). Taken together, EA relieved depression-like behaviors in IBD mice.

EA downregulated the expression of P2Y12 and IL-1β and weakened abnormal activation of microglia in the mPFC of IBD mice

The expression of P2Y12 in the TNBS group was higher than that in the control group (Fig. 7a, d, P < 0.05). EA but not sham EA downregulated the expression of P2Y12
compared with the TNBS group (Fig. 7a, d, P < 0.05). Compared with that in the sham EA group, the expression of P2Y12 in the EA group was downregulated (Fig. 7a, d, P < 0.05). Compared with the control group, the expression of IL-1β was increased in the TNBS group (Fig. 7b, e, P < 0.05). Compared with that in the TNBS group, the expression of IL-1β in the EA group but not the sham EA group was downregulated (Fig. 7b, e, P < 0.05). Compared with that in the sham EA group, the expression of IL-1β in the EA group was downregulated (Fig. 7b, e, P < 0.05). ELISA showed similar trends of IL-1β by western blotting (Fig. 7c, P < 0.05). In summary, EA downregulated the expression of P2Y12 and inhibited IL-1β expression in the mPFC of IBD mice.

Microglia were stained red with IBA-1, and nuclei were stained blue with DAPI (Fig. 8a, b). The percentage of IBA-1-positive cells in the TNBS group was higher than that in the control group. EA but not sham EA decreased the percentage of IBA-1-positive cells compared with the TNBS group. Compared with that in the sham EA

**Fig. 5** P2Y12 shRNA treatment inhibited the activation of microglia in the mPFC of IBD mice. a Representative images showing CD68 immunoreactivity in the mPFC of IBD mice. Represented microglial activated stained red with CD68. Scale bars: 200 μm. b Magnified representative images showing CD68 immunoreactivity in the mPFC of IBD mice. Represented microglial activated stained red with CD68. Scale bars: 50 μm. c CD68 are stained red and nuclei are stained blue with DAPI in the mPFC of IBD mice. Scale bars: 200 μm. d CD68 are stained red and nuclei are stained blue with DAPI in the mPFC of IBD mice. Scale bars: 50 μm. e The percentage of CD68-positive area. Data are presented as the mean ± SEM (n = 3). *p < 0.05, compared with the control + vectors group; #p < 0.05, compared with the TNBS + vectors group
Fig. 6  EA relieved mechanical allodynia, visceral hyperalgesia and depression-like behaviors in IBD mice.  

a Experimental flowchart. 
b Time course of mechanical threshold after EA treatment. 
c Visceral hyperalgesia was evaluated by CRD. 
d After EA treatment, mice's preference for sucrose was recorded as: sucrose consumption(g)/ (sucrose consumption(g) + water consumption(g)) × 100%. 
e Representative results of the effect of the EA treatment on the proportion of floating time in the FST. The proportion of floating time was recorded as: (Floating time(s) / total time(s)) × 100%. 
f Representative results of the effect of the EA treatment on the proportion of immobility time in the TST. The proportion of immobility time was recorded as: (Immobility time(s) / total time(s)) × 100%. The data are expressed as mean ± SEM (n = 7–10 mice). *p < 0.05, compared with the control group; #p < 0.05, compared with the TNBS group; Δp < 0.05, compared with the EA group.
Fig. 7  EA downregulated the expression of P2Y12 and IL-1β in the mPFC. a Representative immunoblots of P2Y12 and β-actin protein expression in the mPFC. b Representative immunoblots of IL-1β and β-actin protein expression in the mPFC. c Enzyme-linked immunosorbent assay results. d Densitometric analysis of P2Y12 protein normalized to the loading control. e Densitometric analysis of IL-1β protein normalized to the loading control. Data are presented as the mean ± SEM (n = 3). *p < 0.05, compared with the control group; #p < 0.05, compared with the TNBS group; Δp < 0.05, compared with the EA group.

Fig. 8  EA changed the morphology of microglia in the mPFC of IBD mice. a IBA-1 are stained red and nuclei are stained blue with DAPI in the mPFC of IBD mice. Scale bars: 200 μm. b IBA-1 are stained red and nuclei are stained blue with DAPI in the mPFC of IBD mice. Scale bars: 50 μm. c The percentage of IBA-1-positive cells, IBA-1-positive cells/somatic cells. Data are presented as the mean ± SEM (n = 3–6). *p < 0.05, compared with the control + vectors group; #p < 0.05, compared with the TNBS + vectors group; Δp < 0.05, compared with the EA group.
group, the percentage of IBA-1-positive cells in the EA group was downregulated (Fig. 8c, \( P < 0.05 \)). Then, activated microglia were stained red with CD68 (Fig. 9a, b), and nuclei were stained blue with DAPI (Fig. 9c, d). Compared with the control group, the percentage of CD68-positive area in the EA group was decreased. Compared with that in the TNBS group, the percentage of CD68-positive area in the EA group was significantly decreased (Fig. 9e, \( P < 0.05 \)). Compared with that in the sham EA group, the percentage of CD68-positive area in the EA group was decreased (Fig. 9e, \( P < 0.05 \)). The data demonstrated that microglial activation was inhibited by EA in the mPFC of IBD mice.

**Discussion**

IBD is defined as chronic relapsing bowel inflammation, including Crohn's disease and ulcerative colitis [28]. As the incidence and prevalence of IBD is increasing

---

**Fig. 9** EA inhibited the activation of microglia in the mPFC of IBD mice. a Representative images showing CD68 immunoreactivity in the mPFC of IBD mice. Represented microglial activated stained red with CD68. Scale bars: 200 μm. b Magnified representative images showing CD68 immunoreactivity in the mPFC of IBD mice. Represented microglial activated stained red with CD68. Scale bars: 50 μm. c CD68 are stained red and nuclei are stained blue with DAPI in the mPFC of IBD mice. Scale bars: 200 μm. d CD68 are stained red and nuclei are stained blue with DAPI in the mPFC of IBD mice. Scale bars: 50 μm. e The percentage of CD68-positive area. Data are presented as the mean ± SEM (n = 4). *\( p < 0.05 \), compared with the control group; #\( p < 0.05 \), compared with the TNBS group; Δ\( p < 0.05 \), compared with the EA group
worldwide, it has become a shared health care problem [29]. Visceral pain is one of the main symptoms of IBD and seriously reduces quality of life [30]. In addition to causing inflammatory reactions, such as visceral pain, IBD is often accompanied by emotional symptoms, such as anxiety and depression [31, 32]. In the past few decades, physicians have focused on the treatment of gastrointestinal symptoms, visceral abdominal pain and diarrhea of IBD but have ignored the accompanying anxiety, depression and other emotional symptoms. In this study, we found that comorbidity of visceral pain and depression-like behaviors occurred in IBD mice and that the expression of P2Y12 was increased in the mPFC of IBD mice. Meanwhile, P2Y12 shRNA alleviated mechanical pain allodynia and visceral hyperalgesia in IBD mice and improved their depression-like behaviors. EA inhibited the expression of P2Y12 and IL-1β in the mPFC and weakened the activation of microglia, thus relieving visceral pain and depression in IBD mice. Therefore, our study provides new information that the P2Y12 receptor is a new target for the clinical treatment of comorbid visceral pain and depression in IBD, which improves our understanding of the underlying mechanisms of EA.

Purinergic receptors play an important role in neurotransmission and gastrointestinal secretory motor functions [33]. The P2Y12 receptor is a metabotropic G protein-coupled purinergic receptor that was first found in platelets and later found to exist in microglia of the central nervous system (CNS) [34–37]. Studies have shown that the P2Y12 receptor is closely related to cancer pain [9] and neuropathic pain [38]. The mPFC is important not only in pain processing but also in the onset of depression-like behaviors [39, 40]. In this study, we found that the expression of P2Y12 was upregulated in the mPFC of IBD mice. Interference with P2Y12 relieved the comorbidity of visceral pain and depression in IBD mice. These results suggest that the P2Y12 receptor in the mPFC could be a new target for the clinical treatment of comorbid visceral pain and depression.

Previous studies have revealed that the expression of the inflammatory factors IL-1β, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the spinal cord is inhibited by selective antagonists of the P2Y12 receptor, which relieves acute and chronic inflammatory pain [9]. In clinical and basic experiments, lines of evidence demonstrated that inflammatory factors not only mediate visceral hyperalgesia but also play a vital role in the comorbidity of visceral pain and depression [41, 42]. Among them, IL-1β is the key molecule mediating the depression-like behaviors induced by acute and chronic stress [12]. For the first time, this study showed that the protein expression of P2Y12 and IL-1β was significantly increased in IBD mice. Interference with the expression of P2Y12 in the mPFC reduced the expression of IL-1β, suggesting that P2Y12 may be upstream of IL-1β. Thus, downregulation of P2Y12 in the mPFC decreased the expression of IL-1β and alleviated the comorbidity of visceral pain and depression in IBD mice. However, this study lacks research on IL-6 and TNF-α, and the mechanism is not deeply explored.

Microglial cells are the primary immune cells of the CNS and play an important role in brain homeostasis and neurological diseases [43]. Previous studies have shown that the activation of the P2Y12 receptor is mainly related to the damage or pathological state of microglia, which in turn activates microglia and causes them to secrete IL-1β [44]. Blocking P2Y12 receptors may inhibit microglial activation, prevent the formation of platelet aggregates, and reduce proinflammatory cytokine levels, which means that P2Y12 inhibitors have not only antithrombotic effects but also neuroprotective effects [45]. IBA-1 is a marker of microglia and CD68 is a marker of activated microglia [46]. Our results showed that both the percentage of IBA-1-positive cells and the percentage of CD68-positive area was significantly increased in IBD mice, indicating that microglia were significantly activated. After P2Y12 shRNA treatment, the activated microglia in the mPFC was decreased. Inhibiting the expression of P2Y12 in the mPFC alleviated visceral pain and depression in IBD mice, weakened the activation of microglia, and reduced the expression of IL-1β in the mPFC. This may be the reason why P2Y12 shRNA treatment alleviated the comorbidity of visceral pain and depression in IBD mice.

As a part of complementary and alternative medicine (CAM), EA has proven to be effective in the treatment of chronic pain [47]. Previous research proved that EA has a significant analgesic effect on visceral pain in mice with IBD [26]. However, it urgently needs to be explored whether EA can improve the incidence of comorbidity of visceral pain and depression. In this study, we found that IBD mice showed obvious mechanical allodynia and visceral hyperalgesia, which were significantly inhibited by EA at acupoint BL25 at frequencies of 1 mA and 2 Hz. These results were consistent with previous research [26]. Interestingly, EA also alleviated depression-like behaviors. For the first time, our results demonstrated the antidepressant effect of EA on IBD mice. EA decreased the expression of P2Y12 and IL-1β as well as the activation of microglia, suggesting that EA downregulated the expression of P2Y12, weakened the activation of microglia, and then inhibited IL-1β expression in the mPFC, thus relieving hyperalgesia and depression in IBD mice (Fig. 10).
Conclusion
The P2Y12 receptor is a purinoceptor that is engaged in platelet aggregation, and P2Y12 inhibitors have been widely used in clinical antithrombotic therapy. For the first time, we found that upregulation of the P2Y12 receptor in the mPFC is associated with the comorbidity of visceral pain and depression. Interference with both P2Y12 shRNA and EA relieved the comorbidity of visceral pain and depression in IBD mice. P2Y12 shRNA and EA significantly downregulated the expression of P2Y12, weakened the activation of microglia, and then inhibited IL-1β expression in the mPFC, thus relieving visceral pain and depression-like behaviors in IBD mice. The present study provided new ideas suggesting that the P2Y12 receptor in the mPFC could be a new target for the clinical treatment of the comorbid visceral pain and depression by EA. This may not only deepen our understanding of the analgesic and antidepressant mechanisms of EA but also promote the application of EA in the clinical treatment of IBD-induced comorbid visceral pain and depression.

Abbreviations
IL-1β: Induce interleukin-1β; EA: Electroacupuncture; IBD: Inflammatory bowel disease; mPFC: Medial prefrontal cortex; TNBS: 2,4,6-Trinitrobenzene sulfonic acid; CRD: Colorectal distension; SPT: Sucrose preference test; TST: Tail suspension test; shRNA: Short hairpin RNA; AWRs: Abdominal withdrawal reflex; CNS: Central nervous system; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α; CAM: Complementary and alternative medicine.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13020-021-00553-9.

Additional file 1: Fig. S1. a The picture of injection site. b The picture of infection area. c The P2Y12 level of mRNA in mPFC.

Acknowledgements
We would like to thank TissueGnostics Asia Pacific limited for their technical support, and the help of Xiaojing Liu, the technical engineer.

Authors’ contributions
ML and JY designed the research. YL, HZ and LY performed the experiments. MY, XH and YL wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by a grant from the National Natural Science Foundation of China (82004491), Funds for the China Postdoctoral Science (2020M682428) and the Scientific Research project of TCM of Hubei Provincial Health Commission (ZY2021M010, ZY2019Z010).
Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
All experimental procedures were reviewed and approved by the Huazhong University of Science and Technology Ethics Committee for Care and Use of Laboratory Animals.

Consent for publication
We declare that the Publisher has the Author's permission to publish the relevant contribution.

Competing interests
The authors declare no competing conflict of interests.

Author details
1 Department of Physiology, Basic Medical College of Nanchang University, Nanchang 330006, China. 2 Department of Physiology, Basic Medical College of Nanchang University, Nanchang 330006, China. 3 Xiangya Hospital of Central South University, Changsha 410000, China.

Received: 3 August 2021   Accepted: 10 December 2021
Published online: 20 December 2021

References
1. Michaelides A, Zis P. Depression, anxiety and acute pain: links and management challenges. Postgrad Med. 2019;131(7):438–44.
2. Vigano CA, et al. Alexithymia and psychopathology in patients suffering from inflammatory bowel disease: arising differences and correlations to tailoring therapeutic strategies. Front Psychiatry. 2018;9:324.
3. Park HY, et al. Psychological characteristics in patients with chronic complex regional pain syndrome: comparisons with patients with major depressive disorder and other types of chronic pain. J Pain Res. 2020;13:389–98.
4. Wouters MM, et al. Altered brain activation to colorectal distention in visceral hypersensitive maternal-separated rats. Neurogastroenterol Motil. 2012;24(7):678–85.
5. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–17.
6. Na SY, Moon W. Perspectives on current and novel treatments for inflammatory bowel disease. Gut Liver. 2019;13(6):604–16.
7. Malik AH, et al. Meta-analysis of dual antplatelet therapy versus mono-therapy with P2Y12 inhibitors in patients after percutaneous coronary intervention. Am J Cardiol. 2020;127:25–9.
8. Rolls F, Franchi F, Angiulli DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13(1):11–27.
9. Liu M, et al. P2Y12-receptor-mediated activation of spinal microglia and p38MAPK pathway contribute to cancer-induced bone pain. J Pain Res. 2017;10:417–26.
10. Horvath G, et al. Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. Neurobiol Dis. 2014;70:162–78.
11. Suzuki T, et al. Extracellular ADP augments microglial inflammation and NF-kappaB activation via the P2Y12 receptor. Eur J Immunol. 2020;50(2):205–19.
12. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineu-rogenic and anhedonic effects of stress. Proc Natl Acad Sci USA. 2008;105(2):751–6.
13. Gu N, et al. Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain. Brain Behav Immun. 2016;53:82–92.
14. Kummer KK, et al. The medial prefrontal cortex as a central hub for mental comorbidities associated with chronic pain. Int J Mol Sci. 2020;21:10.
15. Brockway DF, Crowley NA. Turning the ‘tides’ on neuropsychiatric dis-eases: the role of peptides in the prefrontal cortex. Front Behav Neurosci. 2020;14:588400.
16. Zhao ZQ. Neural mechanism underlying acupuncture analgesia. Prog Neuropsychobiol. 2008;85(4):355–75.
17. Kim JH, et al. The difference between electroacupuncture only and electroacupuncture with manipulation on analgesia in rats. Neurosci Lett. 2000;279(3):149–52.
18. Lao L, et al. A parametric study of electroacupuncture on persistent hyperalgesia and Fos protein expression in rats. Brain Res. 2004;1020(1–2):18–29.
19. Cui KM, et al. Electro-acupuncture relieves chronic visceral hyperalgesia in rats. Neurosci Lett. 2005;376(1):20–3.
20. Yang L, et al. Electroacupuncture upregulates ERK signaling pathways and promotes adult hippocampal neural progenitors proliferation in a rat model of depression. BMC Complement Altern Med. 2013;13:288.
21. dos Santos JG, Jr, et al. Antidepressive-like effects of electroacupuncture in rats. Physiol Behav. 2008;93(1–2):155–9.
22. First M, et al. The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. J Mol Neurosci. 2011;45(2):246–55.
23. Lee B, et al. Effects of acupuncture on chronic corticosterone-induced depression-like behavior and expression of neuropeptide Y in the rats. Neurosci Lett. 2009;453(3):151–6.
24. Liu Q, et al. Electroacupuncture attenuates the decrease of hippocampal progenitor cell proliferation in the adult rats exposed to chronic unpredictable stress. Life Sci. 2007;81(21–22):1489–95.
25. Raffai R, et al. A new acupuncture method for management of irritable bowel syndrome: a randomized double blind clinical trial. J Res Med Sci. 2014;19(10):913–7.
26. Hou T, et al. Electroacupuncture inhibits visceral pain via adenosine receptors in mice with inflammatory bowel disease. Pürinergic Signal. 2019;15(2):193–204.
27. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–17.
28. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(191):1–9.
29. Sarejini T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44(4):673–92.
30. Salameh E, et al. Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase. Am J Physiol Gastrointest Liver Physiol. 2013;316(G3):G692–g700.
31. Bernstein CN. Psychological stress and depression: risk factors for IBD? Dig Dis. 2016;34(1–2):58–63.
32. Jesse CR, Wilhelm EA, Nogueira CW. Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. Psychopharmacology. 2010;212(4):513–22.
33. Christofi FL. Pürinergic receptors and gastrointestinal secretomotor func-tion. Pürinergic Signal. 2008;4(3):213–36.
34. Gelosa P, et al. Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor. J Cereb Blood Flow Metab. 2014;34(6):979–88.
35. Butovsky O, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17(1):131–43.
36. Jing F, et al. P2Y12 receptor mediates microglial activation via RhoA-ROCK pathway in the trigeminal nucleus caudalis in a mouse model of chronic migraine. J Neuroinflam. 2019;16(1):217.
37. Kempthorne L, et al. Loss of homeostatic microglial phenotype in CSFIR-related Leukocytephathap. Acta Neurophilocommun. 2020;8(1):72.
38. Yu T, et al. P2Y12 regulates microglia activation and excitatory synaptic transmission in spinal lamina II neurons during neuropathic pain in rodents. Cell Death Dis. 2019;10(3):165.
39. Ong WY, Stohler CS, Herr DR. Role of the prefrontal cortex in pain process-ing. Mol Neurobiol. 2019;56(2):1137–66.
40. Hare BD, Duman RS. Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions. Mol Psychiatry. 2020;25(11):2742–58.
41. Lin H, et al. Elevated fibrinogenlike protein 2 in TNBS-induced colitis mice: association with Th17 and regulatory T cells. Mol Med Rep. 2017;16(3):3445–54.
42. Zhang X, et al. Protective effect of curcumin on TNBS-induced intestinal inflammation is mediated through the JAK/STAT pathway. BMC Complement Altern Med. 2016;16(1):299.
43. DePaula-Silva AB, et al. Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation. J Neuroinflamm. 2019;16(1):152.
44. Swaroop S, et al. HSP60 critically regulates endogenous IL-1 beta production in activated microglia by stimulating NLRP3 inflammasome pathway. J Neuroinflamm. 2018;15(1):177.
45. Li F, et al. The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells. J Thromb Thrombolysis. 2020;50(4):874–85.
46. Hendrickx DAE, et al. Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology. J Neuroimmunol. 2017;309:12–22.
47. Lv ZT, et al. Effects of intensity of electroacupuncture on chronic pain in patients with knee osteoarthritis: a randomized controlled trial. Arthritis Res Ther. 2019;21(1):120.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.